scholarly journals Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy

HIV Medicine ◽  
2014 ◽  
pp. n/a-n/a ◽  
Author(s):  
C Rokx ◽  
A Verbon ◽  
BJA Rijnders
Keyword(s):  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Inhibitor Therapy ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
K103n Mutation ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection

AIDS ◽  
1998 ◽  
Vol 12 (14) ◽  
pp. 1833-1844 ◽  
Author(s):  
Janis V. Giorgi ◽  
Martin A. Majchrowicz ◽  
Timothy D. Johnson ◽  
Patricia Hultin ◽  
Jose Matud ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Inhibitor Therapy ◽  
Previously Treated ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor

Science ◽  
1990 ◽  
Vol 250 (4986) ◽  
pp. 1411-1413 ◽  
Author(s):  
V. Merluzzi ◽  
K. Hargrave ◽  
M Labadia ◽  
K Grozinger ◽  
M Skoog ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

scholarly journals In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection

2017 ◽  
Vol 61 (7) ◽  
Author(s):  
Nicholas S. Giacobbi ◽  
Nicolas Sluis-Cremer
Keyword(s):  
Reverse Transcriptase ◽  
Genital Tract ◽  
Transcriptase Inhibitor ◽  
Cross Resistance ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Immunodeficiency Virus ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

ABSTRACT Rilpivirine (RPV), dapivirine (DPV), and MIV-150 are in development as microbicides. It is not known whether they will block infection of circulating nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant human immunodeficiency virus type 1 (HIV-1) variants. Here, we demonstrate that the activity of DPV and MIV-150 is compromised by many resistant viruses containing single or double substitutions. High DPV genital tract concentrations from DPV ring use may block replication of resistant viruses. However, MIV-150 genital tract concentrations may be insufficient to inhibit many resistant viruses, including those harboring K103N or Y181C.

Sign in / Sign up

Export Citation Format

Share Document